Paul Choi
Stock Analyst at Goldman Sachs
(3.26)
# 1,045
Out of 4,734 analysts
94
Total ratings
48.39%
Success rate
2.63%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LNTH Lantheus Holdings | Initiates: Buy | $143 | $94.05 | +52.05% | 1 | Dec 18, 2024 | |
| ESPR Esperion Therapeutics | Reinstates: Neutral | $4 | $2.15 | +86.05% | 8 | Dec 18, 2024 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $42 | $45.25 | -7.18% | 7 | Dec 4, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $180 → $200 | $131.06 | +52.60% | 3 | Sep 17, 2024 | |
| CYTK Cytokinetics | Downgrades: Neutral | $85 → $60 | $45.82 | +30.95% | 2 | Aug 13, 2024 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $12 | $6.79 | +76.73% | 7 | Aug 9, 2024 | |
| DVAX Dynavax Technologies | Maintains: Neutral | $20 → $15 | $12.68 | +18.30% | 2 | Aug 8, 2024 | |
| HCM HUTCHMED (China) | Maintains: Neutral | $17 → $19 | $14.21 | +33.71% | 6 | Aug 1, 2024 | |
| GOSS Gossamer Bio | Maintains: Buy | $8 | $0.92 | +767.68% | 4 | Jun 17, 2024 | |
| RGNX REGENXBIO | Initiates: Buy | $38 | $7.57 | +401.98% | 1 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $18.57 | +276.95% | 1 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $18 | $10.19 | +76.64% | 2 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $18.71 | +71.03% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $28 | $10.42 | +168.71% | 7 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $1.5 → $1 | $0.57 | +75.56% | 7 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $36.08 | +38.58% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.41 | +330.84% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $0.53 | +277.29% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $38.98 | +53.93% | 1 | Dec 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.35 | +1,751.85% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $4 | $1.11 | +260.36% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $39.03 | +335.56% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $2.98 | +168.46% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $13.56 | +143.36% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $36.35 | +208.12% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $145.88 | -7.46% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $0.90 | +2,112.39% | 2 | Mar 30, 2020 |
Lantheus Holdings
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $94.05
Upside: +52.05%
Esperion Therapeutics
Dec 18, 2024
Reinstates: Neutral
Price Target: $4
Current: $2.15
Upside: +86.05%
PTC Therapeutics
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $45.25
Upside: -7.18%
Ascendis Pharma
Sep 17, 2024
Maintains: Buy
Price Target: $180 → $200
Current: $131.06
Upside: +52.60%
Cytokinetics
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $45.82
Upside: +30.95%
Phathom Pharmaceuticals
Aug 9, 2024
Maintains: Neutral
Price Target: $10 → $12
Current: $6.79
Upside: +76.73%
Dynavax Technologies
Aug 8, 2024
Maintains: Neutral
Price Target: $20 → $15
Current: $12.68
Upside: +18.30%
HUTCHMED (China)
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $14.21
Upside: +33.71%
Gossamer Bio
Jun 17, 2024
Maintains: Buy
Price Target: $8
Current: $0.92
Upside: +767.68%
REGENXBIO
Jun 7, 2024
Initiates: Buy
Price Target: $38
Current: $7.57
Upside: +401.98%
Feb 1, 2024
Initiates: Buy
Price Target: $70
Current: $18.57
Upside: +276.95%
Jul 31, 2023
Maintains: Neutral
Price Target: $11 → $18
Current: $10.19
Upside: +76.64%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $18.71
Upside: +71.03%
Jul 21, 2023
Maintains: Buy
Price Target: $51 → $28
Current: $10.42
Upside: +168.71%
Jul 20, 2023
Maintains: Sell
Price Target: $1.5 → $1
Current: $0.57
Upside: +75.56%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $36.08
Upside: +38.58%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.41
Upside: +330.84%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.53
Upside: +277.29%
Dec 14, 2022
Initiates: Buy
Price Target: $60
Current: $38.98
Upside: +53.93%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.35
Upside: +1,751.85%
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $1.11
Upside: +260.36%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $39.03
Upside: +335.56%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $2.98
Upside: +168.46%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $13.56
Upside: +143.36%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $36.35
Upside: +208.12%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $145.88
Upside: -7.46%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $0.90
Upside: +2,112.39%